PMID- 32779383 OWN - NLM STAT- MEDLINE DCOM- 20201027 LR - 20201027 IS - 1743-7563 (Electronic) IS - 1743-7555 (Linking) VI - 16 IP - 5 DP - 2020 Oct TI - Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials. PG - e160-e178 LID - 10.1111/ajco.13385 [doi] AB - Programmed cell death receptor-1 and its ligand-1 (PD-1/PD-L1) inhibitors have been applied to many cancers, but the difference of treatment-related adverse events (AEs) across cancer types remains unknown. We performed a meta-analysis and systemic review to compare the incidences of commonly reported all-grade AEs across cancer types and found that the most frequent AEs were fatigue, rash/pruritus, loss of appetite/nausea and diarrhea. However, each cancer type also had its higher incidences of AEs involving a relevant system, such as melanoma with epidermal AEs (rash, diarrhea and enterocolitis), lung cancer with dyspnea and pneumonitis, digestive system cancers with amylase and lipase elevation; and renal cell and urothelial cancer with kidney injury (creatinine elevation and proteinuria). However, the incidence of hepatitis did not follow the pattern to show a difference. We did another comparison between PD-1 and PD-L1 inhibitors in lung cancer and urothelial cancer respectively, and found that the risk of most AEs did not differ much, except for more hypothyroidism in PD-1 inhibitors, and more kidney injury in PD-L1 inhibitors. Besides possible immunological mechanisms for treatment-related AEs, the influence of previous radiotherapy and the clinical characteristics of the diseases themselves should also be considered and is worth further investigation. With the result of this meta-analysis, clinicians could estimate the risk of certain AE in certain cancer type, to make treatment options and to customize monitor strategies. CI - (c) 2020 John Wiley & Sons Australia, Ltd. FAU - Gu, Yangchun AU - Gu Y AUID- ORCID: 0000-0003-3278-7285 AD - Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, P.R. China. FAU - Zhang, Hua AU - Zhang H AD - Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, P.R. China. FAU - Liu, Zexiang AU - Liu Z AD - Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, P.R. China. FAU - Xia, Yifan AU - Xia Y AD - Institute of Medical Technology, Health Science Center, Peking University, Beijing, P.R. China. FAU - Liang, Baosheng AU - Liang B AD - Department of Biostatistics, School of Public Health, Peking University, Beijing, P.R. China. FAU - Liang, Li AU - Liang L AD - Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, P.R. China. LA - eng GR - CAPTRALung2019010/Beijing Cancer Prevention and Treatment Research Association/ PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20200810 PL - Australia TA - Asia Pac J Clin Oncol JT - Asia-Pacific journal of clinical oncology JID - 101241430 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Programmed Cell Death 1 Receptor) SB - IM MH - Antibodies, Monoclonal, Humanized/*adverse effects MH - Humans MH - Immunotherapy/*adverse effects MH - Programmed Cell Death 1 Receptor/*therapeutic use OTO - NOTNLM OT - PD-1/PD-L1 inhibitors OT - cancer types OT - treatment-related adverse event EDAT- 2020/08/12 06:00 MHDA- 2020/10/28 06:00 CRDT- 2020/08/12 06:00 PHST- 2019/08/31 00:00 [received] PHST- 2020/05/13 00:00 [accepted] PHST- 2020/08/12 06:00 [pubmed] PHST- 2020/10/28 06:00 [medline] PHST- 2020/08/12 06:00 [entrez] AID - 10.1111/ajco.13385 [doi] PST - ppublish SO - Asia Pac J Clin Oncol. 2020 Oct;16(5):e160-e178. doi: 10.1111/ajco.13385. Epub 2020 Aug 10.